# Revolution Medicines shares promising data around KRAS drug combination

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-03 21:44 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Executive Summary
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.

## Intelligence Brief
Revolution Medicines presented Phase 1/2 clinical data at the ESMO Gastrointestinal Cancers Congress 2026. The results focus on Zoldonrasib combination regimens, specifically Zoldonrasib plus Daraxonrasib, for patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.


Coverage from Endpoints News, Yahoo Finance, and Oncodaily highlights the promising nature of the data. Medscape describes the findings as practice-changing for GI oncology, while WSAW notes the experimental drug provides additional time and hope for patients.


Future developments center on the application of these combination regimens within gastrointestinal oncology and the progression of the experimental drug's clinical timeline.

## Verified Facts & Key Claims
### What specific cancer is being targeted?
The data focuses on patients with RAS G12D metastatic pancreatic cancer.

### Which drugs are being used in the combination?
The combination involves Zoldonrasib and Daraxonrasib.

### Where was this data presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.

## Key People, Organizations & Locations
KRAS, Anirban, Revolution Medicines, Zoldonrasib Plus Daraxonrasib, Line Metastatic Pancreatic Cancer, Practice-Changing Data, GI Oncology, Revolution Medicines Presents Phase

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Oncodaily | Anirban Maitra։ Data on Zoldonrasib Plus Daraxonrasib in 2nd and 3rd Line Metastatic Pancreatic Cancer | 2026-07-02 15:30 | [Source Link](https://news.google.com/rss/articles/CBMiX0FVX3lxTE43dXRWUlc0a2puVklqX1ViMkhfVndxX3VNanJma0l2QjAyUXZWd2JSQUc1d3Y2dkNoS1Z4eG04Y0djdGszenh4LXhhRV9SYkFfNU5SMF9FSXFRM3BKUGFB?oc=5) |
| Medscape | Practice-Changing Data in GI Oncology | 2026-07-02 15:30 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbWNPM21aYmJhTVgxVzFFTFlXVl8xSUswT0dsaGY3TkZFNjlrb1kySTh6MjNURUxpcVlvNGtjRW9IUi1fZi1odExpd0E0OUg4aTN6ZkdHRkZxaDVpRTgtWUpZY2FjY1M5NHg0MjRWd2YxYm1DTzJ0SENDalZjUGd0MGFKYU1MUFpnUURSRWFYb0c2VVNKRnBrOTNEQmQzNXRwTG5pWTZxdmxORW8?oc=5) |
| Yahoo Finance | Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 | 2026-07-02 15:30 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxOQXVBRnJqcU5sS21KejFhTUNMZmZjTEVxZWNkeXoxUHlWQlVSblF4OTVSSXA4R0stN3pvUGpMRHoxeWtyd1FzTjdTQTUwN245RGFKSS1kUUxQczlsQmFyNjk1a2xTVGFlZjY2UUxka0VBX2FraS1jbEtWU2tEX2xxa0dsWnpDMjRUeTYxc1RwNDI5Q1hrcGlmNmY0b3dybnc?oc=5) |
| WSAW | Experimental cancer drug brings time and hope for patients | 2026-07-02 15:30 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxNSHVUV2NGQkswTkgxYVQwd1hNMUp6Q2JvcFB6OGo0Z2xNWlJDY1FWNlc1OHdKcndGWkJlV2dxcHlwQ1pBQm8wZ1lpNUdtSDR2LTM4UndBWW1nckVsNzRUb0plM2xwVVpfbjh0bnFTalo3M2Z0RFlpaUpQTmI1V3F0SEpYUTBFY0xWYWFF0gGfAUFVX3lxTE5GNE5kOWNHY1RlZXhPOHl3ZjYtamZHRTJsVTY2N2lIQW45akhyOHlzeGt1c0JadHQ0dmlQTkFZLURJVU1FeGp1cktnQWJiUE90TXlZRWY3ZGRyOGgwWWphdXhESDhLaXE1c1ZKa1BuTkhmY1IwZW9KbGpjdWdTT2NVSURLSGt6WHBjenNHMkhHMUQ0RzFYNE1DcFJoMkp1SQ?oc=5) |
| Endpoints News | Revolution Medicines shares promising data around KRAS drug combination | 2026-07-02 15:30 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxNV3hNVTN4WGlYb0pPOGQzSDlLNHE0REUtQ0dScU9YMkNWb2d6bDJPakpmckFzY01UTWlsRE5Rcm05MFZoYmh4ZkhZLTNNN1FyZ3lNTVdQZERadFpQbUJ6LTJ4dWtDNVk5NjA1T0xJckc0YWsxMzR1SkZZTUtvd1lLLW1nN0NpdmRIdERjQmtIQV9fajVxd1N1dDdJcw?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-03/revolution-medicines-shares-promising-data-around-kras-drug-combination*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*